Clinical implications of macrolide therapy in chronic sinopulmonary diseases

Current Pharmaceutical Design

Volumn 10, Issue 25, 2004, Pages 3095-3110

  Martinez, Fernando J ^a,b   Simon, Richard H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CEFACLOR; CLARITHROMYCIN; EOSINOPHIL CATIONIC PROTEIN; ERYTHROMYCIN; GAMMA INTERFERON; IBUPROFEN; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; LEUKOTRIENE B4; MACROLIDE; METHYLPREDNISOLONE; MOXIFLOXACIN; PENICILLIN G; PLACEBO; PREDNISOLONE; ROXITHROMYCIN; TROLEANDOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BACTERIUM CULTURE; BRONCHIECTASIS; BRONCHIOLITIS; CELL TYPE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SPUTUM LEVEL; DYSPNEA; ERADICATION THERAPY; FORCED EXPIRATORY VOLUME; HAEMOPHILUS INFLUENZAE; HUMAN; LUNG LAVAGE; LYMPHOCYTE COUNT; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NOSE POLYP; NOSE SURGERY; PATHOPHYSIOLOGY; PATIENT SELECTION; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; RHINOSINUSITIS; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MACROLIDES; RANDOMIZED CONTROLLED TRIALS; SINUSITIS;

EID: 4544247136     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383304     Document Type: Review

References (140)

1. Koyama H, Geddes D. Erythromycin and diffuse panbronhiolitis. Thorax 1997; 52: 915-8.
2. Nishimura K, Kitaichi M, Izumi T, Itoh H. Diffuse panbronchiolitis: correlation of high resolution CT and pathologic findings. Radiology 1992; 184: 779-85.
3. Akira M, Kitatani F, Lee Y, Kita N, Yamamoto S, Higashihara T, et al. Diffuse panbronchiolitis: evaluation with high-resolution CT. Radiology 1988; 168: 43-8.
4. Izumi T. Diffuse panbronchiolitis (Japanese). Nihon Rinsho 1992; 50 (Suppl): 386-94.
5. Kadota J, Mukae H, Ishii H, Nagata T, Kaida H, Tomono K, et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Resp Med 2003; 97: 844-50.
6. Ichikawa Y, Ninomiya H, Koga H, Tanaka M, Kinoshita M, Tokunaga N, et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis 1993; 147: 1064-5.
7. Mukae H, Kadota J, Kohno S, Kusano S, Morikawa K, Matsukura S, et al. Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. Am J Respir Crit Care Med 1995; 152: 613-8.
8. Kadota J, Mukae H, Tomono K, Kohno S. High concentrations of β-chemokines in BAL fluid of patients with diffuse panbronchiolitis. Chest 2001; 120: 602-7.
9. Hiratsuka T, Mukae H, Lliboshi H, Ashitani J, Nabeshima K, Minematsu T, et al. Increased concentration of human β-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax 2003; 58: 425-30.
10. Oishi K, Sonoda F, Kobayashi A, Iwagaki A, Nagatake T, Matsushima K, et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 1994; 62: 4145-52.
11. Oda H, Kadota J, Kohno S, Hara K. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest 1994; 106: 1116-23.
12. Kadota J, Sakito O, Kohno S, Sawa H, Mukae H, Oda H, et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 147: 153-9.
13. Sakito O, Kadota J, Kohno S, Abe K, Shirai R, Hara K. Interleukin 1β, tumor necrosis factor-α, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63: 42-8.
14. Homma H, Yamanaka A, Tanimoto S, Tamura M, Chijimatsu Y, Kira S, et al. Diffuse panbronchiolitis: a disease of the transitional zone of the lung. Chest 1983; 83: 63-9.
15. Kudoh S, Kimura K, Uetake K, et al. Abstract of annual meeting. Jpn J Thorac Dis 1984; 22: 254.
16. Kudoh S, Uetake T, Hagiwara K, Hirayama M, Hus L-H, Kimura H, et al. Clinical effect of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis (English Abstract). Jpn J Thorac Dis 1987; 25: 632-42.
17. Yamamoto M. Therapeutic effect of erythromycin in patients with DPB-double blind trial (Japanese). Annual report on the study of diffuse disseminated interstitial lung disease, Grant-in-aid from the Ministry of Health and Welfare in Japan 1991; 18-20.
18. Sawaki M, Mikami R, Mikasa K, Kunimatsu M, Ito S, Narita N. The long term chemotherapy with erythromycin in chronic lower respiratory tract infections - Second report: including cases with Pseudomonas infections (English Abstract). J Jpn Assoc Infect Dis 1986; 60: 45-50.
19. Nagai A, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991; 58: 145-9.
20. Ohno S, Sugiyama Y, Kitamura S. Clinical effects of low-dose and long-term erythromycin in diffuse panbronchiolitis with chronic respiratory failure (Engish Abstract). Jpn J Thorac Dis 1993; 31: 1251-6.
21. Takeda H, Miura H, Kawahira M, Kobayashi H. Long-term administration study on TE-031 (A-56268) in treatment of diffuse panbronchiolitis (English Abstract). J Jpn Assoc Infect Dis 1989; 63: 71-8.
22. Ashitani J, Doutsu Y, Taniguchi H, Ii T, Matsukura S. A case of diffuse panbronchiolitis relieved rapidly by the treatment of roxithromycin (Japanese). J Jpn Assoc Infect Dis 1992; 66: 657-8.
23. Nakamura H, Fujishima S, Inoue T, Ohkubo Y, Soejima K, Waki Y, et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J 1999; 13: 1371-9.
24. Kobayashi H, Takeda H, Sakayori S, Kawakami Y, Otsuka Y, Tamura M, et al. Study on azithromycin in treatment of diffuse panbronchiolitis (English abstract). J Jpn Assoc Infect Dis 1995; 69: 711-22.
25. Akira M, Higashihara T, Sakatani M, Hara H. Diffuse panbronchiolitis: follow-up CT examination. Radiology 1993; 189: 559-62.
26. Ichikawa Y, Hotta M, Sumita S, Fujimoto K, Oizumi K. Reversible airway lesions in diffuse panbronchiolitis. Detection by high-resolution computed tomography. Chest 1995; 107: 120-5.
27. Fujii T, Kadota J, Kawakami K, Iida K, Shirai R, Kaseda M, et al. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995; 50: 1246-52.
28. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998; 157: 1829-32.
29. Hamilos D. Chronic sinusitis. J Allergy Clin Immunol 2000; 106: 213-27.
30. Tedeschi A, Palumbo G, Milazzo N, Miadonna A. Nasal neutrophilia and eosinophilia induced by challenge with platelet activating factor. J Allergy Clin Immunol 1994; 93: 526-33.
31. Demoly P, Crampete L, Mondain M, Campbell A, Lequeux N, Enander I, et al. Assessment of inflammation in noninfectious chronic maxillary sinusitis. J Allergy Clin Immunol 1994; 94: 95-108.
32. Bachert C, Van Cauwenbérge P. Inflammatory mechanisms in chronic sinusitis. Acta Otorhinolaryngol 1997; 51: 209-17.
33. Rhyoo C, Sanders S, Leopold D, Proud D. Sinus mucosal IL-8 gene expression in chronic rhinosinusitis. J Allergy Clin Immunol 1999; 103: 395-400.
34. Demoly P, Crampete L, Mondain M, Enander I, Jones I, Bousquet J. Myeloperoxidase and interleukin-8 levels in chronic sinusitis. Clin Exp All 1997; 27: 672-5.
35. Takeuchi K, Yuta A, Sakakura Y. Interleukin-8 gene expression in chronic sinusitis. Am J Otolaryngol 1995; 16: 98-102.
36. Slavin R. Sinusitis in adults and its relation to allergic rhinitis, asthma, and nasal polyps. J Allergy Clin Immunol 1988; 82: 950-6.
37. Hamilos D, Leung D, Wood R, Meyers A, Stephens J, Barkans J, et al. Chronic hyperplastic sinusitis: association of tissue eosinophilia with mRNA expression of granulocyte-macrophage colony-stimulating factor and interleukin-3. J Allergy Clin Immunol 1993; 92 (1 Pt 1): 39-48.
38. Hamilos D, Leung D, Wood R, Cunningham L, Bean D, Yasruel Z, et al. Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis. J Allergy Clin Immunol 1995; 96: 537-44.
39. Hamilos D, Leung D, Wood R, Bean D, Song Y, Schotman E, et al. Eosinophil infiltration in nonallergic chronic hyperplastic sinusitis with nasal polyposis (CHS/NP) is associated with endothelial VCAM-1 upregulation and expression of TNF-alpha. Am J Respir Cell Mol Biol 1996; 15: 443-50.
40. Hashiba M, Baba S. Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol (Stockh) 1996; Suppl 525: 73-8.
41. Rhee C, Majima Y, Arima S, HW J, Hinn T, Min Y, et al. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. Ann Otol Rhinol Laryngol 2000; 109: 484-7.
42. Nishi K, Mizuguchi M, Tachibana H, Ooka T, Amemiya T, Myou S, et al. Effect of clarithromycin on symptoms and mucociliary transport in patients with sino-bronchial syndrome. Nippon Kyobu Shikkan Gakkai Zasshi 1995; 33: 1292-400.
43. Suzuki H, Shimorua A, Ikeda K, Oshima T, Takasaka T. Effects of long-term macrolide administration on neutrophil recruitment and IL-8 in the nasal discharge of chronic sinusitis patients. Tohoku J Exp Med 1997; 182: 115-24.
44. Suzuki H, Asada Y, Ikeda K, Oshima T, Takasaka T. Inhibitory effect of erythromycin on Interleukin-8 secretion from exudative cells in the nasal discharge of patients with chronic sinusitis. Laryngoscope 1999; 109: 407-10.
45. Sutherland E, Martine R. Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol 2003; 112: 819-27.
46. Douwes J, Gibson P, Pekkanen J, Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002; 57: 643-8.
47. O'Donnell R, Frew A. Is there more than one inflammatory phenotype in asthma? Thorax 2002; 57: 566-8.
48. Niven A, Argyros G. Alternate treatments in asthma. Chest 2003; 123: 1254-65.
49. Evans D, Cullinan P, Geddes D, Walters E, Jones P. Troleandomycin as an oral corticosteroid sparing agent in stable asthma. Cochrane Database Syst Rev 2003; 3.
50. Ball B, Hill M, Brenner M, Sanks R, Szefler S. Effect of low-dose troleandomycin on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic children. Ann Allergy 1990; 65: 37-45.
51. Kamada A, Hill M, Ikle D, Brenner M, Szefler S. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 1993; 91: 873-82.
52. Nelson H, Hamilos D, Corsello P, Levesque N, Buchmeier A, et al. A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids. Am Rev Respir Dis 1993; 147: 398-404.
53. Miyatake H, Taki F, Taniguchi H, Suzuki R, Takagi K, Satake T. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma. Chest 1991; 99: 670-3.
54. Shimizu T, Kato M, Mochizuki H, Tokuyama K, Morikawa A, Kuroume T. Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma. Chest 1994; 106: 458-61.
55. Kamoi H, Kurihara N, Fujiwara H, Hirata K, Takeda T. The macrolide antibacterial roxithromycin reduces bronchial hyperresponsiveness and superoxide anion production by polymorphonuclear leukocytes in patients with asthma. J Asthma 1995; 32: 191-7.
56. Garey K, Rubinstein I, Gotfried M, Khan I, Varma S, Danziger L. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 2000; 118: 1826-7.
57. Richeldi L, Ferrara G, Fabbri L, Gibson P. Macrolides for chronic asthma. Cochrane Database Syst Rev 2003; 3.
58. Amayasu H, Yoshida S, Ebana S, Yamamoto Y, Nishikawa T, Shoji T, et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000; 84: 594-8.
59. Shoji T, Yoshida S, Sakamoto H, Hasegawa H, Nadagawa H, Amayasu H. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp All 1999; 29: 950-6.
60. Kraft M, Cassell G, Pak J, Martin R. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma. Effect of clarithromycin. Chest 2002; 121: 1782-8.
61. Black P, Blasi F, Jenkins C, Scicchitano R, Mills G, Rubinfeld A, et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001; 164: 536-41.
62. Ward MM, Javitz HS, Smith WM, Bakst A. Direct medical cost of chronic obstructive pulmonary disease in the U.S.A. Respir Med 2000; 94: 1123-9.
63. Grasso ME, Weller WE, Shaffer TJ, Diette GB, Anderson GF. Capitation, managed care, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 133-8.
64. Ruchlin HS, Dasbach EJ. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics 2001; 19: 623-42.
65. Hilleman D, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000; 118: 1278-85.
66. Barnes PJ. Therapy of chronic obstructive pulmonary disease. Pharmacol Ther 2003; 97: 87-94.
67. Hill A, Campbell E, Hill S, Bayley D, Stockley R. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109: 288-95.
68. Wedzicha J. Exacerbations. Etiology and pathophysiologic mechanisms. Chest 2002; 121: 136S-41S.
69. Seemungal T, Donaldson G, Paul E, Bestall J, Jeffries D, Wedzicha J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-22.
70. Doll H, Grey-Amante P, Duprat-Lomon I, Sagnier P, Thate-Waschke I, Lorenz J, et al. Quality of life in acute exacerbation of chronic bronchitis: results from a German population study. Resp Med 2002; 96: 39-51.
71. 1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 358-64.
72. Donaldson G, Seemungal T, Bhowmik A, Wedzicha J. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-52.
73. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-45.
74. Aaron S, Angel J, Lunau M, Wright K, Fex C, Le Saux N, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 349-355.
75. Saetta M, Di Stefano A, Maestrelli P, Turato G, Ruggieri MP, Roggeri A, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994; 150: 1646-52.
76. Balbi B, Bason C, Balleari E, Fiasella F, Pesci A, Ghio R, et al. Increased bronchoalveolar granulocytes and granulocyte/ macrophage colony-stimulating factor during exacerbations of chronic bronchitis. Eur Respir J 1997; 10: 846-50.
77. Bhowmik A, Seemungal T, Sapsford R, Wedzicha J. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114-20.
78. Gompertz S, O'Brien C, Bayley D, Hill S, Stockley R. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001; 17: 1112-9.
79. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J 2002; 20 (Suppl 36): 9s-19s.
80. Sethi S, Murphy T. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001; 14: 336-63.
81. Wilson R. Bacteria, antibiotics and COPD. Eur Respir J 2001; 17: 995-1007.
82. Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, et al. Bacterial infection in chronic obstructive pulmonary disease: A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152: 1316-1320.
83. Fagon J, Chastre J, Trouillet J, Domart Y, Dombret M, Bornet M, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990; 142: 1004-8.
84. Soler N, Torres A, Ewig S, Gonzalez J, Celis R, El-Ebiary M, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498-1505.
85. Pela R, Marchesani F, Agostinelli C, Staccioli D, Cecarini L, Basotti C, et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Arch Chest Dis 1998; 53: 262-7.
86. Zalacain R, Sobradillo V, Amilibia J, Barron J, Achotegui V, Pijoan J, et al. Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. Eur Respir J 1999; 13: 343-8.
87. Bandi V, Apicella MA, Mason E, Murphy TF, Siddiqi A, Atmar RL, et al. Nontypeable Haemophilus influenzae in the Lower Respiratory Tract of Patients with Chronic Bronchitis. Am. J. Respir. Crit. Care Med 2001; 164: 2114-2119.
88. Groeneveld K, Eijk P, van Alphen L, Jansen H, Zanen H. Haemophilus influenzae infections in patients with chronic obstructive pulmonary disease despite specific antibodies in serum and sputum. Am Rev Respir Dis 1990; 141: 1316-21.
89. Yi K, Sethi S, Murphy T. Human immune response to non-typable Haemophilus influenzae in chronic bronchitis. J Infect Dis 1997; 176: 1247-52.
90. Bandi V, Jakubowycz M, Kinyon C, Mason E, Atmar R, Greenberg S, et al. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable Haemophilus influenzae. FEMS Immunol Med Microbiol 2003; 37: 69-75.
91. Sethi S, Wrona C, Grant B, Murphy T. Strain specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 448-53.
92. Sethi S, Evans N, Grant B, Murphy T. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. New Eng J Med 2002; 347: 465-71.
93. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542-8.
94. Miravitlles M, Espinosa C, Fernandez-Laso E, Martos J, Maldonado J, Gallego M, COPD. SGoBli. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Chest 1999; 116: 40-6.
95. O'Brien C, Guest P, Hill S, Stockley R. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55: 635-42.
96. Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 1015-22.
97. Bresser P, Out TA, van Alphen L, Jansen HM, Lutter R. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 947-52.
98. Patel I, Seemungal T, Wilks M, Lloyd-Owen S, Donaldson G, Wedzicha J. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759-64.
99. Sethi S, Muscarella K, Evans N, Klingman K, Grant B, Murphy T. Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest 2000; 118: 1557-65.
100. White A, Gompertz S, Bayley D, Hill S, O'Brien C, Unsal I, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680-5.
101. Wilson R, Kubin R, Ballin I, Deppermann K, Bassaris H, Leophonte P, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44: 501-13.
102. Suzuki T, Yanai M, Yamaya M, Satoh-Nakagawa T, Sekizawa K, Ishida S, et al. Erythromycin and common cold in COPD. Chest 2001; 120: 730-3.
103. Gomez J, Baños V, Simarro E, Lorenzo Cruz M, Gomez J, Latour J, et al. Estudio prospective y comparative (1994-1998) sobre la influencia del tratamiento corto profilactico con azitromicina en pacientes con EPOC evolucionada. Rev Esp Quimioterap 2000; 13: 379-83.
104. Barker A. Bronchiectasis. New Eng J Med 2003; 346: 1383-93.
105. Hansell D. Bronchiectasis. Radiol Clin North Am 1998; 36: 107-28.
106. Gaga M, Bentley A, Humbert M, Barkans J, O'Brien F, Wathen C, et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 1998; 53: 685-91.
107. Richman-Eisenstat J, Jorens P, Hebert C, Ueki I, Nadel J. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol 1993; 264: L413-8.
108. Tsang K, Chan K, Ho P, Zheng L, Ooi G, Ho J, et al. Sputum elastase in steady-state bronchiectasis. Chest 2000; 117: 420-6.
109. Angrill J, Agusti C, De Celis R, Filella X, Raño A, Elena M, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164: 1628-32.
110. Ho P, Chan K, Ip M, Lam W, Ho C, Yuen K, Tsang K. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest 1998; 114: 1594-8.
111. Tsang K, Ho P, Chan K, Ip M, Lam W, Ho C, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999; 13: 361-4.
112. Koh Y, Lee M, Sun Y, Sung K, Chae J. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997; 10: 994-9.
113. Tagaya E, Tamaoki J, Kondo M, Nagai A. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 2002; 122: 213-8.
114. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57: 212-216.
115. Equi A, Balfour-Lynn M, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002; 360: 978-984.
116. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, CQuittner AL, Cibene DA, Coquillett S, Fieberg AY, Accurso FJ, Cambell PW, III. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. A randomized controlled trial. JAMA 2003; 290: 1749-1756.
117. Cystic Fibrosis Foundation Registry. 2002 Annual Data Report to Center Directors 2003; 21.
118. Nguyen T, Louie SG, Beringer PM, Gill MA. Potential rle of macrolide antibiotics in the management of cystic fibrosis lung disease. Curr Opin Pulm Med 2002; 8: 521-528.
119. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001; 31: 464-473.
120. Anderson R. Erythromeyin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activation superoxide generation and autooxidation. J Infect Dis 1989; 159: 966-973.
121. Khair OA, Devalia JL, Abdelaziz MM, Sapsford RJ, Davies RJ. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8, and sICAM-1 by cultured human bronchial epithelia cells. Eur Respir J 1995; 8: 1451-1457.
122. Schultz MU, Speelman P, Van der Poll T. Erythromycin inhibitis Pseudomonas aeruginosa-induced tumor necrosis factor-alpla production in human whole blood. J Antimicrob Chemother 2001; 48: 275-278.
123. Matthews WJ Jr, Williams M, Oliphint B, Geha R, Colten HR. Hypogammaglobulinemia in patients with cystic fibrosis. N Engl J Med 1980; 302: 245-9.
124. Auerbach HS, Williams M, Kirkpatrick JA, Colten HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 2: 686-8.
125. Liu T, Adler F, Cahill B, FitzSimmons S, Huang D, Hibbs J, Marshall B. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA 2001; 286: 2683-9.
126. Liu T, Adler F, FitzSimmons S, Cahill B, Hibbs J, Marshall B. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153: 345-52.
127. Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss C, Aitken M. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002; 166: 1550-5.
128. Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 1995; 126: 515-23.
129. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848-54.
130. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-82.
131. DiMango E, Ratner AJ, Bryan R, Tabibi S, Prince A. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J Clin Invest 1998; 101: 2598-605.
132. Jaffe A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998; 351: 420.
133. Hotta M. Neutrophil chemotactic activity in cryptogenic organizing pneumonia and the response to erythromycin. Kurume Med J 1996; 43: 207-217.
134. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003; 168: 121-5.
135. Society AT. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54.
136. Lynch III J, Martinez F. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Inf Dis 2002; 34: S27-46.
137. Kudoh S. The diagnostic criteria for diffuse panbronchiolitis. Ministry of Health and Welfare in Japan 1995.
138. Korsgren M. NK cells and asthma. Curr Pharm Design 2002; 8(20): 1871-6.
139. Reid P. T, Sallenave J. M. Cytokines in the pathogenesis of chronic obstructive pulmonary disease. Curr Pharm Design 2003; 9(1): 25-38.
140. Tripp R. A. Role of cytokines in the development and maintenance of memory T cells during respiratory viral infection. Curr Pharm Design 2003; 9(1): 51-9.